Salud financiera de hoja de balance de BioXcel Therapeutics

Salud financiera controles de criterios 2/6

BioXcel Therapeutics tiene un patrimonio de los accionistas total de $-56.5M y una deuda total de $100.6M, lo que sitúa su ratio deuda-patrimonio en -178%. Sus activos y pasivos totales son $73.7M y $130.2M respectivamente.

Información clave

-178.0%

Ratio deuda-patrimonio

US$100.60m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$65.22m
Patrimonio	-US$56.51m
Total pasivo	US$130.21m
Activos totales	US$73.70m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Aug 28

BioXcel Therapeutics Q2 2022 Earnings Preview

Aug 08

BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset

Jul 19

BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar Patients

May 18

Análisis de la situación financiera

Pasivos a corto plazo: BTAI tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: BTAI tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: BTAI tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: BTAI tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BTAI tiene suficiente cash runway para 5 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que BTAI disponga de suficiente cash runway para 8 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de BioXcel Therapeutics

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

BioXcel Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Consensus revenue estimates fall by 13%

Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Price target decreased by 22% to US$7.42

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

BioXcel Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.1% to US$9.50

BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.0% to US$10.80

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®

BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

New minor risk - Market cap size

Consensus revenue estimates increase by 18%

New major risk - Negative shareholders equity

BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

BioXcel Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Bioxcel Therapeutics, Inc. Receives Permanent J-Code for Igalmi (Dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

BioXcel Therapeutics, Inc. Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (Dexmedetomidine) Sublingual Film

BioXcel Therapeutics, Inc. Announces Board Changes

Independent Chairman & Lead Director notifies of intention to sell stock

Bioxcel Therapeutics, Inc. Receives Notice of Allowance from the U.S. Patent and Trademark Office

Consensus revenue estimates decrease by 48%, EPS upgraded

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023

BioXcel Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 12% to US$48.00

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Bioxcel Therapeutics, Inc

New major risk - Share price stability

BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

Price target decreased by 9.4% to US$46.50

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell Small Cap Comp Value Index

Founder exercised options and sold US$593k worth of stock

Bioxcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal Security Iii Trial of Bxcl501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 13%

BioXcel Therapeutics, Inc., Annual General Meeting, Jun 26, 2023

Senior VP & CFO exercised options and sold US$136k worth of stock

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MAD) Program

Chief Digital Officer ?& Director exercised options and sold US$1.0m worth of stock

Consensus revenue estimates decrease by 26%

Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 11%

Consensus revenue estimates fall by 42%

No longer forecast to breakeven

Forecast to breakeven in 2025

Price target increased by 7.6% to US$54.90

Bioxcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 Asco Genitourinary Cancers Symposium

Price target increased by 9.4% to US$50.78

Insider exercised options and sold US$879k worth of stock

Chief Digital Officer ?& Director exercised options and sold US$1.3m worth of stock

BioXcel Therapeutics, Inc. Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Founder exercised options and sold US$1.2m worth of stock

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

BioXcel Therapeutics, Inc. Announces First Patients Dosed in Serenity III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

Consensus forecasts updated

Chief Digital Officer ?& Director exercised options and sold US$875k worth of stock

Insufficient new directors

BioXcel Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Consensus forecasts updated

Price target decreased to US$49.20

Consensus revenue estimates fall by 65%

BioXcel Therapeutics Q2 2022 Earnings Preview

BioXcel Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioXcel Therapeutics, Inc. Receives Two Notices of Allowance from the U.S. Patent and Trademark Office

BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset

Price target decreased to US$49.50

BioXcel Therapeutics, Inc. Announces That Its Product, Igalmi™ (Dexmedetomidine), A Sublingual Film for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults, Is Now Available in Doses of 120 and 180 Mcg